Event Examines Key Clinical Trial Adaptation Trends
Applied Clinical Trials
Clinical trial optimization through adaptation in several key areas was a prevailing message at the recent Partnerships Conference.
Clinical trial optimization has been a popular theme so far this year at many industry trade events, including the recent Partnerships in Clinical Trials Conference in Las Vegas. Optimization through adaptation in several key areas was a prevailing message at this year's event. Three such areas are highlighted here.
Risk-based monitoring
There was considerable dialogue focused on the varying strategies of risk-based monitoring (RBM) implementation. Large biopharmaceutical companies spoke about their RBM infrastructures, with Amgen, specifically, detailing its approach, which involves vertically integrating risk-based analysis internally while outsourcing on-site monitoring via the functional service provider (FSP) model. Meanwhile, medium-sized companies expressed concerns that they are still struggling to grasp how to best leverage RBM techniques, as FDA's guidance on the matter remains open to interpretation, and other guidances in the industry are not applicable to companies of their scale. TransCelerate BioPharma Inc., a non-profit organization comprised of pharmaceutical and biotechnology companies, provided updates on new initiatives surrounding site qualification and training, shared investigator portals, clinical data standards, and comparator drug standardization.
Outsourcing and operational strategy optimization
Astellas discussed its relationship with Parexel, a CRO, emphasizing the importance of optimizing budgetary forecasts and moving beyond transactional cultures to focus on patient safety and data integrity outcomes. Goldman Sachs reported that clinical outsourcing has nearly doubled over the past several years, and clinical research remains an attractive sector for private equity investors. Price-to-earnings ratios in the CRO sector are five times their valuations.
Patient involvement and centricity
A new trend is developing in clinical research: patients are becoming involved with communicating their perspectives and experiences to clinical operations staff. During a conference panel, several patients described their concerns with poorly designed trials involving unnecessary visits, and the time commitment and financial burden typically placed on the patient. Sponsors are starting to incorporate patients more in the trial-design process, through interviews and obtaining qualitative feedback during the protocol design phase.
— Moe Alsumidaie
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
